Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Vote in favor of your Favored sort of footwear - 2Ergonomic Office Seats for Work spaces
- 3More parents refusing this shot that prevents serious bleeding at birth
- 4Independence from the rat race for Recent college grads: Systems and Tips
- 5Apollo's impatient old-timers are rooting for NASA's return to the moon with Artemis II launch
- Israel scales back use of top missile interceptors as Iran barrages persist
- Iranian naval commander Alireza Tangsiri killed in attack, says Israel
- Toyota Motor Europe to roll out smart EV charging through new partnerships
- Storm Goretti sweeps United Kingdom, France with winds over 120 mph
- Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
- Nikki Glaser has been testing out Golden Globes jokes. There's one nobody wants to hear
- Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- Flourishing in Retirement: Individual Accounts of Post-Vocation Satisfaction
- Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts.
